(Q30847905)

27 June 2017

1 reference

Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis (English)

1 reference

27 June 2017

0 references

0 references

1 reference

1 reference

4

Douglas G Altman

1 reference

27 June 2017

Dipak Kotecha

1

0 references

Paulus Kirchhof

object named as

Paulus Kirchhof

10

0 references

Gregory Lip

7

object named as

Gregory Y H Lip

1 reference

27 June 2017

3

Henry Krum

1 reference

27 June 2017

13

Giuseppe Rosano

1 reference

27 June 2017

8

Andrew J S Coats

1 reference

27 June 2017

11

Thomas G von Lueder

1 reference

27 June 2017

15

Alan Rigby

1 reference

27 June 2017

9

Bert Andersson

1 reference

27 June 2017

14

Marcelo C Shibata

1 reference

27 June 2017

6

John G F Cleland

1 reference

27 June 2017

Jane Holmes

2

1 reference

27 June 2017

Luis Manzano

5

1 reference

27 June 2017

Hans Wedel

12

1 reference

27 June 2017

Marcus D Flather

16

1 reference

27 June 2017

Beta-Blockers in Heart Failure Collaborative Group

17

1 reference

27 June 2017

language of work or name

English

0 references

publication date

2 September 2014

1 reference

27 June 2017

1 reference

27 June 2017

volume

384

1 reference

27 June 2017

issue

9961

1 reference

27 June 2017

page(s)

2235-2243

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

27 June 2017

1 reference

7 January 2021

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Rehospitalization for heart failure: predict or prevent?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Hospital readmissions in US atrial fibrillation patients: occurrence and costs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

What are the costs of heart failure?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left V

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Effect of carvedilol on survival in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Empirical comparison of subgroup effects in conventional and individual patient data meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Trends in Heart Failure Incidence and Survival in a Community-Based Population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Is heart rate important for patients with heart failure in atrial fibrillation?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Effect of an irregular ventricular rhythm on cardiac output

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation .

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961373-8

7 January 2021

10.1016/S0140-6736(14)61373-8

Identifiers

DOI

1 reference

27 June 2017

1 reference